Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Reuters NewMedia - December 16, 2004
GSK's Arxitra -- an ex-Sanofi product which it was forced to sell when it merged with Aventis -- is now recommended for patients at high risk of thromboembolic complications because of cardiac insufficiency, acute respiratory disorders, or acute infectious or inflammatory disease.
Arixtra, which is also known as Quixidar, was first approved in 2002 for preventing deep vein thrombosis following major hip or knee surgery.
The Committee for Medicinal Products for Human Use also backed wider use of Roche's Pegasys, in combination antiviral therapy with ribavirin, for the treatment of chronic hepatitis C in patients co-infected with HIV.
Recommendations by the committee are normally endorsed by the European Commission within 90 days.
041216
RE041249
Copyright © 2004 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .